You are here

Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41MD008829-01
Agency Tracking Number: R41MD008829
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIMHD
Solicitation Number: MD13-009
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
8070 Georgia Ave Suite 416
SILVER SPRING, MD 20910-4948
United States
DUNS: 802841069
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (215) 680-8286
Business Contact
Phone: (240) 401-9343
Research Institution
WASHINGTON, DC 20010-2916
United States

 () -
 Domestic Nonprofit Research Organization

DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory properties, in small clinical trials have been shown to reduce the duration of analgesic therapy in children with pain crisis, and in SCD patients admitted with acute chest syndrome, a course of dexamethasone decreased hospitalization time. However, clinicians hesitate to prescribe steroids to treat steroid-responsive conditions in SCD patients because their use is associated with complications that include increased risk of hospital readmission, rebound pain, strokes, avascular necrosis, and acute chest syndrome. Further, some steroid-responsive conditions such as asthma have a high incidence in SCD; however, because of

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government